Home › Companies › CCCC

C4 Therapeutics, Inc.

CCCC Lead: Phase 2 3 Biotech Distilled articles ↓

Oncology Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (2 active programs)

cemsidomide

Small Molecule Target: IKZF1, IKZF3, IKZF1/3

Multiple Myeloma Phase 2 oral Pfizer

CFT8919

Small Molecule

Undisclosed indication Phase 1 Betta Pharma

Technology platforms

TORPEDO

Proprietary targeted protein degradation platform — collection of computational and experimental tools for designing, analyzing, and predicting degrader performance; supports MonoDAC (molecular glue type) and BiDAC (heterobivalent) degraders with properties such as oral bioavailability, CNS penetration, enhanced potency, and selectivity; focus on oncology, inflammation, neuroinflammation, and neurodegeneration

BIDAC · Roche

Bivalent degrader antibody conjugate platform technology used in collaboration with Roche for discovering and developing DACs against oncology targets.

Discontinued (1)

CFT8919 — Non-Small Cell Lung Cancer · strategic deprioritization due to evolving treatment landscape, capital priorities, and available clinical data

Biotech Distilled coverage (3)

2026-05-12 UPDATE: C4 Therapeutics (CCCC) - The CFT8919 Bonfire and the All-In Bet on Cemsidomide 🔒 Paid
2026-04-11 UPDATE: C4 Therapeutics (CCCC) - Roche Validates the DAC Modality and Pads the Balance Sheet 🔒 Paid
2026-04-01 C4 Therapeutics (CCCC) - Scientific Deep Dive for Cemsidomide and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.